PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2856823

Renal response to converting enzyme blockade.

P W de Leeuw·P N van Es·M Looman·W H Birkenhäger
View original source ↗Export metadata ↓

Abstract

To investigate the renal actions of the converting enzyme inhibitor enalaprilic acid, incremental doses of this drug were infused into the renal artery of hypertensive patients just before renal angiography. One group (n = 6) received doses of 0.1, 0.3 and 1 microgram/kg per min, while in another group (n = 7) doses of 1, 3 and 10 micrograms/kg per min were given. Each dose was infused for 10 min, at the end of which renal blood flow was assessed by means of xenon-washout. At the same time, blood was sampled from the renal artery and vein for determination of converting enzyme, renin and angiotensin II. Enalaprilic acid caused a dose-related suppression of converting enzyme activity, which was maximal at a dose of 1 microgram/kg per min; arterial levels fell more steeply than venous ones. Angiotensin II disappeared in parallel with the drop in converting enzyme. Renal blood flow, on the other hand, began to increase only when 3 micrograms/kg per min was given, and no further changes occurred with the highest dose. Intra-arterial blood pressure fell only when the highest dose was given. Renin secretion tended to increase, but changes were not statistically significant. It is concluded that systemic suppression of converting enzyme is needed for renal vasodilatation to occur. However, the renal vascular response comes well before blood pressure falls.

Explore related subjects

Angiotensin-Converting Enzyme InhibitorsEnalaprilatFemaleHumansHypertensionKidneyMaleRenal CirculationJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P W de Leeuw, P N van Es, M Looman, W H Birkenhäger. 1985. Renal response to converting enzyme blockade.. https://pubmed.ncbi.nlm.nih.gov/2856823/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Rapid quantification of lisinopril in human plasma by liquid chromatography/tandem mass spectrometry.

An assay based on protein precipitation and liquid chromatography/tandem mass spectrometry (LC-MS/MS) has been developed and validated for the quantitative analysis of lisinopril in human plasma. After the addition of enalaprilat as internal standard (IS), plasma samples were prepared by one-step protein precipitation using perchloric acid followed by an isocratic elution with 10 mm ammonium acetate buffer (pH adjusted to 5.0 with acetic acid)-methanol (70:30, v/v) on a Phenomenex Luna 5 mu C(18) (2) column. Detection was performed on a triple-quadrupole mass spectrometer utilizing an electrospray ionization (ESI) interface operating in positive ion and selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 406 --> 246 for lisinopril and m/z 349 --> 206 for enalaprilat. Calibration curves of lisinopril in human plasma were linear (r = 0.9973-0.9998) over the concentration range 2-200 ng/mL with acceptable accuracy and precision. The limit of detection and lower limit of quantification in human plasma were 1 and 2 ng/mL, respectively. The validated LC-MS/MS method has been successfully applied to a preliminary pharmacokinetic study of lisinopril in Chinese healthy male volunteers.

Angiotensin-Converting Enzyme Inhibitors↗
PubMed2007

Renin-induced hypertension in Wilms tumor patients.

BACKGROUND: Since the report that hypertension associated with Wilms tumor (WT) may be renin-induced, no larger series than 13 patients have been published. Nevertheless, angiotensin converting enzyme (ACE) inhibitors have become treatment of choice for hypertension in WT patients. The purpose of this study was to investigate the correlation between plasma renin levels and blood pressure in a larger cohort of WT patients. PROCEDURE: In this retrospective, single-center study, data on blood pressure and plasma renin were analyzed in 86 WT patients treated according to the consecutive SIOP protocols 6, 9, 93-01, and 2001. RESULTS: At diagnosis, 47 WT patients suffered from hypertension (55%). In 31 of these patients plasma renin levels were analyzed; increased plasma renin levels were found in 25/31 patients (81%). In contrast, normal plasma renin levels were measured in 8/13 of the patients with a normal blood pressure (P = 0.012). Twenty-eight children received antihypertensive treatment before surgery, in 25 of them blood pressure normalized before surgery. Blood pressure was normal directly after surgery in all patients but 4, in whom blood pressure recovered to normal within a few weeks. CONCLUSIONS: This retrospective study shows that hypertension in WT patients is associated with elevated plasma renin levels, indicating that ACE inhibitors may be a good therapeutic option in at least a subset of WT patients with hypertension before nephrectomy.

Angiotensin-Converting Enzyme Inhibitors↗